Peficitinib

Peficitinib is an oral Janus kinase inhibitor developed by Astellas Pharma for the treatment of rheumatoid arthritis. It is currently approved for use in Japan and is undergoing clinical trials in other countries.

Mechanism of Action[edit | edit source]

Peficitinib works by inhibiting the Janus kinase (JAK) family of enzymes, which are involved in the signaling pathways of various cytokines and growth factors that are important for hematopoiesis and immune cell function. By inhibiting these enzymes, peficitinib can reduce inflammation and other symptoms of rheumatoid arthritis.

Clinical Trials[edit | edit source]

Peficitinib has undergone several clinical trials to evaluate its safety and efficacy in treating rheumatoid arthritis. In a Phase 3 trial conducted in Japan, peficitinib was found to be effective in reducing the signs and symptoms of rheumatoid arthritis, and had a safety profile consistent with other JAK inhibitors.

Side Effects[edit | edit source]

Common side effects of peficitinib include nausea, diarrhea, and upper respiratory tract infection. Serious side effects can include anemia, neutropenia, and thrombocytopenia. Patients taking peficitinib should be monitored for these and other potential side effects.

References[edit | edit source]

Peficitinib Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.